Research Publications

Clopidogrel is associated with better in-hospital and 30-day outcomes than ticlopidine after coronary stenting.

L'Allier PL, Aronow HD, Cura FA, Bhatt DL, Albirini A, Schneider JP, Topol EJ, Ellis SG

August 1, 2003

Frequency of stent thrombosis after acute coronary syndromes (from the SYMPHONY and 2nd SYMPHONY trials).

Tolleson TR, Newby LK, Harrington RA, Bhapkar MV, Verheugt FW, Berger PB, Moliterno DJ, White HD, Ohman EM, Van de Werf F, Topol EJ, Califf RM, SYMPHONY and the 2nd SYMPHONY Investigators

August 1, 2003

Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease.

Topol EJ, Easton D, Harrington RA, Amarenco P, Califf RM, Graffagnino C, Davis S, Diener HC, Ferguson J, Fitzgerald D, Granett J, Shuaib A, Koudstaal PJ, Theroux P, Van de Werf F, Sigmon K, Pieper K, Vallee M, Willerson JT, Blockade of the Glycoprotein IIb/IIIa Receptor to Avoid Vascular Occlusion Trial Investigators

July 29, 2003

N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy.

James SK, Lindahl B, Siegbahn A, Stridsberg M, Venge P, Armstrong P, Barnathan ES, Califf R, Topol EJ, Simoons ML, Wallentin L

July 22, 2003

Effect of revascularization on mortality associated with an elevated white blood cell count in acute coronary syndromes.

Bhatt DL, Chew DP, Lincoff AM, Simoons ML, Harrington RA, Ommen SR, Jia G, Topol EJ, PURSUIT Investigators

July 15, 2003

Effect of abciximab versus tirofiban on activated clotting time during percutaneous intervention and its relation to clinical outcomes--observations from the TARGET trial.

Casserly IP, Topol EJ, Jia G, Lange RA, Hamm C, Meier B, DiBattiste PM, Lakkis N, Chew DP, Stone GW, Cohen DJ, Moliterno DJ

July 15, 2003

Research Publications

Clopidogrel is associated with better in-hospital and 30-day outcomes than ticlopidine after coronary stenting.

Frequency of stent thrombosis after acute coronary syndromes (from the SYMPHONY and 2nd SYMPHONY trials).

Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease.

N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy.

Effect of revascularization on mortality associated with an elevated white blood cell count in acute coronary syndromes.

Effect of abciximab versus tirofiban on activated clotting time during percutaneous intervention and its relation to clinical outcomes--observations from the TARGET trial.

Using C-reactive protein to assess cardiovascular disease risk.

Increased expression of thrombospondin-1 in vessel wall of diabetic Zucker rat.

Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials.

Integrin alphaIIbbeta3 and its antagonism.